Akeso Inc
HKEX:9926

Watchlist Manager
Akeso Inc Logo
Akeso Inc
HKEX:9926
Watchlist
Price: 76.85 HKD 0.07% Market Closed
Market Cap: 68.8B HKD
Have any thoughts about
Akeso Inc?
Write Note

Akeso Inc
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Akeso Inc
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Akeso Inc
HKEX:9926
Intangible Assets
ÂĄ8.5m
CAGR 3-Years
90%
CAGR 5-Years
112%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Intangible Assets
ÂĄ982.3m
CAGR 3-Years
41%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Intangible Assets
ÂĄ642.7m
CAGR 3-Years
40%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Intangible Assets
ÂĄ227.3m
CAGR 3-Years
11%
CAGR 5-Years
4%
CAGR 10-Years
8%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Intangible Assets
ÂĄ1.4B
CAGR 3-Years
4%
CAGR 5-Years
27%
CAGR 10-Years
18%
Imeik Technology Development Co Ltd
SZSE:300896
Intangible Assets
ÂĄ114.9m
CAGR 3-Years
123%
CAGR 5-Years
67%
CAGR 10-Years
N/A
No Stocks Found

Akeso Inc
Glance View

Market Cap
66.5B HKD
Industry
Biotechnology

Akeso Inc. is an innovative biopharmaceutical company that has carved out a distinctive niche in the treatment of cancer and autoimmune diseases. With its headquarters in Zhuhai, China, Akeso is focused on developing cutting-edge therapies driven by its proprietary bispecific antibody platform. This platform allows the company to create multifunctional antibodies that can simultaneously target different pathways, potentially enhancing the effectiveness of treatments while minimizing side effects. Akeso's lead product, the PD-1 monoclonal antibody, AK104, has been making significant strides with promising results in clinical trials, positioning the company as a formidable player in the competitive oncology landscape. As the global demand for novel therapeutics grows, Akeso is not just resting on its laurels. The company has an impressive pipeline of candidates that address various hematological malignancies and autoimmune disorders, indicating a strong commitment to broadening its therapeutic reach. Additionally, Akeso's strategic partnerships, including collaborations with major global pharmaceutical firms for development and commercialization, bolster its potential for growth and market penetration. For investors, Akeso represents a compelling opportunity as it navigates the complexities of drug development and regulatory approval, poised to transform the landscape of treatment options available to patients and carve out a lasting presence in the biopharmaceutical sector.

Intrinsic Value
43.87 HKD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Akeso Inc's Intangible Assets?
Intangible Assets
8.5m CNY

Based on the financial report for Dec 31, 2023, Akeso Inc's Intangible Assets amounts to 8.5m CNY.

What is Akeso Inc's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
112%

Over the last year, the Intangible Assets growth was 0%. The average annual Intangible Assets growth rates for Akeso Inc have been 90% over the past three years , 112% over the past five years .

Back to Top